Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.525
+0.1151.22%
Volume:190.28M
Turnover:1.84B
Market Cap:109.75B
PE:24.04
High:9.980
Open:9.505
Low:9.430
Close:9.410
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.04
T/O Rate:1.65%
Dividend:0.29
Dividend Rate:3.04%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.50
PE(LYR):24.04
PS:3.00

Loading ...

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Yesterday

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Yesterday

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Yesterday

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Yesterday

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Yesterday

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Yesterday

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Yesterday

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Yesterday

Movement Alert|CSPC PHARMA Rises 3.13% in Regular Trading, RSV Vaccine Receives FDA Clinical Trial Approval While Multiple Banks Raise Target Prices

Market Focus
·
Yesterday

CSPC Pharma secures U.S. FDA clearance for Phase I trial of second recombinant RSV vaccine SYS6057

Bulletin Express
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25

CSPC Says FDA Clears RSV Vaccine Candidate SYS 6057 for US Clinical Trial

Reuters
·
Aug 25

CSPC Pharmaceutical - Recombinant Respiratory Syncytial Virus Vaccine (Sys6057) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 25

CSPC Pharmaceutical - Sys6057 Receives Nmpa Approval on July 30, 2026 to Conduct Clinical Trials in China

THOMSON REUTERS
·
Aug 25

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live
·
Aug 24

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 24

Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results

Stock News
·
Aug 24

Movement Alert|CSPC PHARMA Rises 4.46% in Regular Trading, Multiple Investment Banks Raise Target Prices Post-Earnings

Market Focus
·
Aug 24